Line 116: |
Line 116: |
| Various experimental studies are conducted to study the effect of herbs in reducing atherosclerosis. The animals were first fed with high fat, high cholesterol diet. As a result, the endothelium of vessels gets deposited with fatty tissues (atherosclerosis), which is considered as the primary cause for blockages. Then the same animals were fed with CAD reversal herbs like Garcinia indica (Vrikshamla) for six weeks. Garcinia treatment protected the endothelium from atherosclerosis.The endothelium becomes intact without any fatty tissue deposition.<ref>Kim, Young-Je & Choi, Myung-Sook & Park, Yong & Kim, Sang & Lee, Mi-Kyung & Jung, Un. (2013). Garcinia Cambogia attenuates diet-induced adiposity but exacerbates hepatic collagen accumulation and inflammation. World journal of gastroenterology : WJG. 19. 4689-701. 10.3748/wjg.v19.i29.4689.</ref> | | Various experimental studies are conducted to study the effect of herbs in reducing atherosclerosis. The animals were first fed with high fat, high cholesterol diet. As a result, the endothelium of vessels gets deposited with fatty tissues (atherosclerosis), which is considered as the primary cause for blockages. Then the same animals were fed with CAD reversal herbs like Garcinia indica (Vrikshamla) for six weeks. Garcinia treatment protected the endothelium from atherosclerosis.The endothelium becomes intact without any fatty tissue deposition.<ref>Kim, Young-Je & Choi, Myung-Sook & Park, Yong & Kim, Sang & Lee, Mi-Kyung & Jung, Un. (2013). Garcinia Cambogia attenuates diet-induced adiposity but exacerbates hepatic collagen accumulation and inflammation. World journal of gastroenterology : WJG. 19. 4689-701. 10.3748/wjg.v19.i29.4689.</ref> |
| | | |
− | Image 1. Effect of garcinia indica in atherosclerosis | + | [[File:Image 1.JPG|500px|'''Image 1: Effect of garcinia indica in atherosclerosis '''|thumb]] |
| | | |
| ==Sampurna Hridaya Shuddhikaran (SHS) therapy== | | ==Sampurna Hridaya Shuddhikaran (SHS) therapy== |
Line 149: |
Line 149: |
| In a randomized controlled trial, one group (Arm A) received HFRT (Heart failure reversal therapy) with conventional oral medications for heart failure. The other group (Arm B) received only conventional oral medications. VO2 max in Arm B group was 19.02ml/kg/min initially. After six weeks of conventional treatment, VO2 max increased to 21.9ml/kg/min. After 18 weeks, it again raised to 24.02 ml/kg/min. The initial VO2 max in Arm A patients was 19.65 ml/kg/min, almost equal to that of Arm B. After six weeks of therapy VO2 max raised to 28.01 ml/kg/min, and after 18 weeks of therapy, it again raised to 29.12 ml/kg/min.<ref>Sane R, Aklujkar A, Patil A, Mandole R. Effect of heart failure reversal treatment as add-on therapy in patients with chronic heart failure: A randomized, open-label study. Indian Heart J. 2017 May-Jun;69(3):299-304. doi: 10.1016/j.ihj.2016.10.012. Epub 2016 Nov 18. PMID: 28648417; PMCID: PMC5485380.</ref> [Image 2] This shows the significant advantage of HFRT over conventional treatment in heart failure. | | In a randomized controlled trial, one group (Arm A) received HFRT (Heart failure reversal therapy) with conventional oral medications for heart failure. The other group (Arm B) received only conventional oral medications. VO2 max in Arm B group was 19.02ml/kg/min initially. After six weeks of conventional treatment, VO2 max increased to 21.9ml/kg/min. After 18 weeks, it again raised to 24.02 ml/kg/min. The initial VO2 max in Arm A patients was 19.65 ml/kg/min, almost equal to that of Arm B. After six weeks of therapy VO2 max raised to 28.01 ml/kg/min, and after 18 weeks of therapy, it again raised to 29.12 ml/kg/min.<ref>Sane R, Aklujkar A, Patil A, Mandole R. Effect of heart failure reversal treatment as add-on therapy in patients with chronic heart failure: A randomized, open-label study. Indian Heart J. 2017 May-Jun;69(3):299-304. doi: 10.1016/j.ihj.2016.10.012. Epub 2016 Nov 18. PMID: 28648417; PMCID: PMC5485380.</ref> [Image 2] This shows the significant advantage of HFRT over conventional treatment in heart failure. |
| | | |
− | Image 2 | + | [[File:Image 2.JPG|500px|'''Image 2: Heart failure reversal therapy on VO2max'''|thumb]] |
| | | |
| ====Efficacy in ischemic heart disease==== | | ====Efficacy in ischemic heart disease==== |
Line 156: |
Line 156: |
| through SPECT MPI.<ref>Rohit S, Jagdish H, Chandrakant C, Sujit N, Rahul M (2020) Ischemia Reversal Therapy as an add-on Therapy for Ischemic Heart Disease: A Pilot Study based on SPECT Myocardial Perfusion Imaging. J Cardiovasc Dis Diagn 8: 397.</ref> | | through SPECT MPI.<ref>Rohit S, Jagdish H, Chandrakant C, Sujit N, Rahul M (2020) Ischemia Reversal Therapy as an add-on Therapy for Ischemic Heart Disease: A Pilot Study based on SPECT Myocardial Perfusion Imaging. J Cardiovasc Dis Diagn 8: 397.</ref> |
| | | |
− | Image 3: Ischemia Reduction on Myocardial Perfusion through SPECT MPI | + | [[File:Image 3.JPG|500px|'''Image 3: Ischemia Reduction on Myocardial Perfusionthrough SPECT MPI'''|thumb]] |
| | | |
| ====Effect on left ventricular distress==== | | ====Effect on left ventricular distress==== |
Line 168: |
Line 168: |
| As per various published data, the survival rate of various cardiac interventions is shown below. [Image 4] | | As per various published data, the survival rate of various cardiac interventions is shown below. [Image 4] |
| | | |
− | Image 4.Survival rate after cardiac interventions | + | [[File:Image 4.JPG|500px|'''Image 4: Survival rate after cardiac interventions'''|thumb]] |
| | | |
| ==Conclusion== | | ==Conclusion== |